Mannan Pharmaceuticals LLC, an organization dedicated to developing and delivering effective pharmaceutical solutions to various muscular dystrophies and metastatic cancers, will establish operations at the Institute for Translational Oncology Research (ITOR) of Greenville Health System (GHS) in Greenville County. Mannan plans to expand its research and development team to create up to 34 new positions over the next several years.
“We believe that ITOR provides an ideal environment for Mannan to develop solutions to various muscular dystrophies [MDs] and metastatic cancers,” said Dr. Xiaohua Wu, senior executive with Mannan Pharmaceuticals LLC, in a press release. “Some of the most advanced cancer treatments anywhere in the world are being offered at ITOR, which provides organizations like ours with the services, technologies and facilities required to develop life-saving drugs for patients in need.”
Mannan is the first pharmaceutical company to pioneer development of compound-based drugs that target a novel pathway to treat various MDs and metastatic cancers, according to the release. Mannan Pharmaceuticals’ drugs in development are anticipated to target more than half of all MD patients, a drug market estimated at nearly $15 billion.
Mannan is a privately held company, and had been considering locations nationwide before deciding to open at ITOR, Dr. Wu noted. Mannan expects to add up to three more associates in 2014 and then will continue to grow and expand its team as “investment and developments warrant.”